The relation between elevated stool calprotectin and inflammatory bowel diseases
DOI:
https://doi.org/10.26719/LJMR.18.2.02Keywords:
fecal,, calprotectin, IBD, patient,, invasiveAbstract
Background: Inflammatory bowel disease (IBD) is a long-life disease with remission and relapse periods. IBD arises due to an inappropriate immune response and consequently causes inflammation and intestinal ulcers. Performing colonoscopy and inflamed bowel biopsy specimens for histopathological evaluation are currently considered the gold standard for diagnosing and managing IBD. These techniques are costly and invasive. In recent decades fecal calprotectin as a biomarker has received much attention for the diagnosis and non-invasive management of IBD. Aim: To assess the role of elevated fecal calprotectin as a prerequisite to suspect active and relapsed IBD.Method: Two hundred patients with endoscopic biopsy-proven IBD were enrolled in this study which was started in January 2021 to December 2023, all patients were negative for HBsAg, anti-HCV, HIV., negative Covid-19 PCR test, normal D-Dimer, normal CRP, normal coagulation profile (PT & INR). Result: Thirty patients (15%) with a diagnosis of UC (ulcerative colitis) at the time of presentation have high fecal calprotectin > 200 μg/g, and 30 patients (15%) with a diagnosis of UC at relapse have also high fecal calprotectin > 200 μg/g, the remaining 50 patients (25%) with a diagnosis of UC have normal fecal calprotectin < 50 μg/g. Twenty-five patients (12.5%) with a diagnosis of CD (Crohn´s disease) at the time of presentation have high fecal calprotectin > 200 μg/g, and 45 patients (22.5%) with a diagnosis of CD at relapse also have high fecal calprotectin > 200 μg/g, the remaining 20 patients (10%) with a diagnosis of CD have normal fecal calprotectin.Conclusion: Incorporating fecal calprotectin as a valuable noninvasive biomarker for managing IBD can significantly enhance patient care by providing timely and accurate information on disease activity and treatment response, an alternative to frequent endoscopies or imaging studies
Downloads
References
Abraham C. Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009; 361:2066-2078. Doi: 10.1056/NEMra0804647. PubMed PMID:19923578; PubMed Central PMCID: PMCPMC3491806.
Tamboli C. P. Neut C. Desreumaux P., Colombel J.F. Dysbiosis in inflammatory bowel disease. Gut. 2004; 53:1-4. Doi:10.1136/gut.53.1.1. PubMed PMID:14684564; PubMed Central PMCID: PMCPMC1773911.
Vaghari Tabari M., Moein S., Qujeq D., Kashifard M., Shokri Shirvani J., Hajian Tilaki K., et al. Evaluation of the potential antioxidant role of high-density lipoprotein-e A., cholesterol (HBL-C) in patients with ulcerative colitis. Ann Colorectal Res. 2017;5: e13699. Doi: 10.5812/acr.13699.
Zeng Z., Mukherje A., Zhang H. From genetics to epigenetics, roles of epigenetics in inflammatory bowel disease. Front. Genet. 2019; 10:1017. Doi: 10.3389/fgene.2019.01017. PubMed PMID:31737035; PubMed Central PMCID: PMCPMC6834788.
Carter M.J., Lobo A.J., Travis S .P. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5): V1-V16. Doi: 10.1136/gut.2004.043372. PubMed PMID: 15306569; PubMed Central PMCID: PMCPMC1867788.
Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60:571-607. Doi: 10.1136/gut.2010.224154. PubMed PMID: 2146096.
Levine J.S., Burakoff R. Extra intestinal manifestation of inflammatory bowel disease. Gastroenerol. Hepatol. (N Y). 2011; 7:235-241. PubMed PMID: 21857821; PubMed Central PMCID: PMCPMC3127025.
Solem C.A., Lofus E.V., Jr., Tremaine W. J., Pemberton J.H., Wolf B.G., Sandborn W.J. Fistulas to the urinary system in crohn´s disease: clinical features and outcomes. Am.J. Gastroenterol. 2002; 97:2300-2305. Doi: 10 .1111/j. 1572-0241.2002.05983. x. PubMed PMID: 12358248.
Antunes C.V., Hallack Neto A.E., Nascimento C.R. Chebli L.A., Moutinho I.L., Pinherio Bdo V., et al. Anemia in inflammatory bowel disease out-patients: prevalence, risk factors, and etiology. Bioomed. Res. Int. 2015; 2015:728925.
Sykora J., Pomahacova R., Kreslova M., Cvalinova D. Stych P. Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J. Gastroenterol. 2018; 24:2741-2763.
Ng S.C., Shi H.Y. Hamidi N., Underwood F.E., Tang W., Benchimol E.I., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390:2769-2778. Doi: 10.1016/s0140-6736(17)32448-0. PubMed PMID: 29050646.
Johnston R.D., Logan R.F. What is the peak age for onset of IBD? Inflamm. Bowel Dis. 2008;14(Suppl 2): S4-S5. Doi: 10.1002/ibd. 20545. PubMed PMID:18816745.
Bharadwaj S., Narula N., Tandon P., Yaghoobi M. Role of endoscopy in inflammatory bowel disease. Gastroenterol. Rep. (oxf). 2018; 6:75-82.
Joshi S. Lewis S.I., CreanorS., S.J., Creanor s., Aling R, M. Age-related fecal calprotectin, lactoferrin and tumour M2-PK concentration in healthy volunteers. Ann.Clin. Biochem. 2010; 47:259-263. Doi: 10.1258/acb.2009.009061. PubMed PMID: 19740914.
Naess-Andresen C.F., Egelandsdal B., Fagerhol M.K. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein) Clin Mol Pathol. 1995;48:M278-M284.
Haisma S.M., Van Rheenen P.F., Wagenmakers L., Muller K.A. Calprotectin instability may lead to under treatment in children with IBD. Arch. Dis. Child. 2019 doi: 10.1136/archdischild-2018-316584. PubMed PMID: 30655264.
Roseth A.G., Fagerhol M.K., Aadland E., Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J. Gastroenterol. 1992; 27:793-798. Doi: 10.3109/00365529209011186. PubMed PMID: 1411288.
Roseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a noval granulocyte marker protein. Digestion. 1997; 58:176-180. Doi: 10.1159/000201441. PubMed PMID: 9144308.
Moein S., Qujeq D., Vaghari Tabari M., Kashifard M., Hajian-Tilaki K Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J, Int. Med. 2017;8:178-182. Doi: 10.22088/cjm.8.3.178. PubMed PMID: 28932369; PubMed Central PMCID: PMCPMC5596188.
Waugh N., Cummins E., Royle P., Kandala N.B., Shyangdan D., Arasaradnam R., et al. Fecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel disease: systemic review and economic evaluation. Health Technol. Assess. 2013:17 doi: 10.3310/hta17550. Xv-xix, 1-211. PubMed PMID: 24286461; PubMed Central PMCID: PMCPMC4781415.
Shergil A.K., Ben-Menachen T., Chandrasekhara V., Chathadi K., Decker G.A., Evans J.A., et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest. Endosc. 2012; 76:18-24. Doi: 10.1016/jgie. 2012.02.029. PubMed: 22579258.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Samira Alkuni S Omar, , Malak Mohamed M Allafi, Maram Abdulhamid A Alssid (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
